The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into Phase I trials, with additional preclinical assets targeting Parkinson’s and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback